Abstract
Outsourcing of drug discovery has
become common practice driven by the desire to increase flexibility and cost-effectiveness
as well as providing specialist services.
Focussing on single aspects, such
as cost for example, can lead to a situation where teams, often in different
companies, work separately providing data, results and molecules meant to
satisfy the same objective of delivering a high quality drug candidate.
As
such, the challenges of managing multiple providers, the lack of cross
communication and loss of oversight of the programme can reduce the benefits of
outsourcing leading to delays, rising costs, and increasing risk of failure.
At Pharmaron, we offer expert led
and fully integrated drug discovery platforms, alongside extensive capacity, blended
with innovative technologies to create an environment that significantly
increases the probability of success:
1. Modern hit-finding capabilities, such as DNA-Encoded
Library Technology (DELT), combined with world-class synthetic chemistry and led
by expert medicinal chemists.
2. Expert in
vivo pharmacology and co-located biological screening to receive compounds
straight from chemistry to expedite Design-Make-Test-Analyse (DMTA) cycles.
3. A comprehensive in vitro and in vivo DMPK
screening cascade with results reported and interpreted alongside biological
data.
4. Scientific leadership and programme management
ensuring timely delivery.
Here we present and discuss with
key examples how our extensive range of capabilities and large capacity meet
our expertise in all scientific disciplines through a well-coordinated and
smart use of resources to deliver drug candidates of exceptional quality in a
cost-effective manner.
